TWC
RAPP

TD Waterhouse Canada’s Rapport Therapeutics RAPP Stock Holding History

TD Waterhouse Canada’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.84K Buy
+123
New +$4.52K ﹤0.01% 1987

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TD Waterhouse Canada's RAPP Position: Q2 2026 in Review

TD Waterhouse Canada opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 123 shares worth $4.84K. The stake represents ﹤0.01% of the portfolio and ranks #1987 among its holdings.

54 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • TD Waterhouse Canada held 123 shares of Rapport Therapeutics worth $4.84K as of Q2 2026.
  • Rapport Therapeutics was a new TD Waterhouse Canada position in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1987 holding.
  • 54 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.